Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Activating mutations in RAS family proteins are found in ~25% of all human cancers. Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten RAS (KRAS) being the most frequently mutated isoform. Historically, KRAS has been acknowledged as "undruggable",...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Bog |
Udgivet: |
MDPI AG,
2021-05-01T00:00:00Z.
|
Fag: | |
Online adgang: | Connect to this object online. |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
Vær først til at give en kommentarø!